Today, we’re proud to announce that OURA has raised $200M in Series D funding led by Fidelity Management & Research Company and Dexcom, the global leader in glucose biosensing. With this investment, Oura’s valuation has surpassed $5.2 billion, a milestone that validates our mission and approach. Founded in Oulu, Finland, more than 11 years ago, Oura’s mission then was the same as it is today; in the simplest terms, it’s to help all people live healthier lives. In the last decade, we’ve expanded our product offering, invested deeply in science, research, and validation, expanded our retail footprint and partnership portfolio, and doubled down in specific health areas like women’s health, heart health, stress & resilience, metabolic health, and more. We'll use this investment to expand our product offerings, fuel further investment in product, science, and healthcare innovation, including AI, advance global expansion efforts, and explore additional acquisitions to accelerate growth. More from TechCrunch: https://lnkd.in/g2fdpRfQ
Fantastic update
the Dexcom tie up is interesting for blood sugar monitoring. how about diet? see DiabeticU for a possible software collaboration. exciting to see this innovation from Finland Health!
Wenjing Dai
3mo
Congrats!
Hernan Benavides
3mo
Congratulations!
Albert Morales
3mo
With this new fresh funding, you should be able now to stop charging your customers for using the software after having paid for quite an expensive hardware. Otherwise you'll start to see big shift to Ultrahuman, Samsung and others that will come with free-of-use software. What a lovely UX you offer to your customers. Never seen that before. Not sure is going to look fine for the brand having lots of Oura rings being sold on Ebay and other P2P marketplaces. Mine is there already to be sold.
colin malone
3mo
Yawn
Unicage
3mo
We can help you grow your revenue by sharing insights on your clients’ behaviour.
Chari Sutherland
2mo
Fantastic update
Congratulations!